Pharmacokinetics of Flunarizine Hydrochloride After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food Effects

• Published in: Clinical pharmacology in drug development 2022-03, Vol.11 (3), p.341-347
• Main Authors: Xu, Yan‐Ying, Yi, Zhi‐Heng, Li, Xiao‐Min, Li, Dai, Pan, Lin, Dai, Yi‐Xin, Zhong, Xue‐Feng, Yan, Juan, Xu, Ping‐Sheng, Xu, Su‐Mei
• Format: Article
• Language: English
• Subjects: Bioequivalence; bioequivalent; Confidence intervals; evaluation; flunarizine; food effects; Oral administration; Pharmacokinetics; Plasma
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.1012

We designed a study to compare the newly developed 5‐mg flunarizine hydrochloride capsules (test) to that of its marketed counterpart (5‐mg; reference) among healthy adult Chinese volunteers. We performed an open‐label, single‐center study that consisted of 2 randomized, crossover trials, including a fasting trial and a fed trial. In each part of the study, the subjects were randomly assigned to either receive the test or reference products (5‐mg flunarizine) in a 1:1 ratio. Subjects then received the alternative products, following a 14‐day washout period. Concentrations of plasma flunarizine were analyzed using liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters (noncompartmental model) were evaluated using the WinNonlin software. The analysis of variance and Food and Drug Administration bioequivalence statistical criterion of 90% confidence interval for 80% to 125% range (set at P ≤ .05) of geometric means ratios of test: reference product for peak plasma concentration, area under the plasma concentration–time curve (AUC) from time 0 to time t, and AUC from time 0 to infinity were determined. Tolerability was evaluated during the entire study period. Overall, 23 volunteers completed the fasting study, while 40 volunteers completed the fed study. The test formulation was found to be bioequivalent to the marketed formulation, as the 90% confidence interval for the ratio of geometric means of peak plasma concentration (fasting: 87.61%‐101.67%; fed: 87.38%‐104.06%), AUC from time 0 to time t (fasting: 89.44%‐99.92%; fed: 92.65%‐98.28%), and AUC from time 0 to infinity (fasting: 95.02%‐104.33%; fed: 90.41%‐96.96%) were within equivalence limits (80–125%) under both the fasting and fed conditions. When flunarizine was given alongside high‐fat meals, time to maximum concentration was delayed ≈3.5 hours compared to fasting conditions. Meantime, high‐fat meals increased its exposure by nearly 50%. Furthermore, there were no serious adverse events found among the subjects. This study confirmed that test and reference flunarizine hydrochloride capsules were bioequivalent under fasting and postprandial conditions.